Development of gene therapies for rare ocular and central nervous system diseases using AAV-ligand conjugates for targeted delivery.
B
CSR Analysis score
The organization is among the top 20% of most committed organizations, excluding the top 5%, among comparable organizations.
+160,000
Total organizations analyzedAnalysis by axis
Access the detailed report with all sector benchmarks, in-depth competitive analysis and actionable recommendations.
Methodology: Score calculated according to 6 CSR themes (Carbon, Biodiversity, Circular Economy, Sustainable Investments, Governance, Social Impact)
Sources: Public data, CSR reports, documented initiatives, official databases
Last update: March 2026
This analysis is not yet available in English. Please see the French version.
Leading organizations
GenSight Biologics
B
Development of gene therapies for the treatment of blindness, focusing on mitochondrial targeting and optogenetics.
Genethon
B
Research and development of gene therapy medicines for the treatment of rare diseases.
Cellectis
B
Development of cell and gene therapies using gene editing to treat cancer and other diseases. The company uses its TALEN® technology to create off-the-shelf allogeneic CAR T cells.
Initiatives identified among leaders
Développement d'un environnement de travail coopératif
“Genethon développe un environnement de travail coo...” - GenethonDéveloppement d'une culture inclusive
“Cellectis met en place des actions pour promouvoir...” - CellectisObtention du statut d'établissement pharmaceutique
“Genethon obtient le statut d'établissement pharmac...” - Genethon38% of similar organizations communicate on CSR issues
+178 initiatives collected from 50 similar organizations
Is your score incomplete? Update your CSR information and improve your positioning.
Claim this page
Updated data
Personalized recommendations
Access complete data, competitive analyses and actionable recommendations for your clients.
Comprehensive sector benchmarks
Competitive data
Ready-to-use reports